Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 68.56M.
Subavaliada
O PE mais recente da empresa é -3.05, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 130.35M ações, um aumento de 6.85% em relação ao trimestre anterior.
Mantido por ETHSX
O Super Investidor ETHSX possui 600.00K ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.33.